Chiima Therapeutics is a pre-clinical, early-stage biotech company committed to developing innovative therapies that focus on women’s health. We are currently investigating our lead compound, CHM-001 for the non-hormonal treatment of moderate to severe endometriosis-related pain in adult women. This compound has robust IP protection that includes disease-modifying effects and a paid reduction in endometriosis. We conducted our final meeting with the US Patent & Trademark Office to secure a composition of matter and method of treatment patent for patients with endometriosis. Endometriosis-related pain control is a significant clinical challenge that has been largely unmet. Endometriosis affects an estimated 1 in 10 women during their reproductive years, which is approximately 200 million women in the world. Our other lead compound, CHM-002 is being investigated for the treatment of pre-term labor. In the United States, preterm delivery affects approximately 1 in 10 births and is the cause of at least 75% of neonatal deaths. Approximately 15 million preterm neonates are born annually and more than 1 million die from subsequent complications within the following 5 years. Our pre-clinical data in both molecules have demonstrated positive Proof of Concept and efficacy data and a tolerable safety profile. We are currently finalizing our IND studies, preparing for clinical phase 1 first in human use, and continuing our pre-IND meeting conversations with the FDA and pre-CTA meetings with EMA. We also have a pre-NDA meeting with The National Medical Products Administration of China in Q2. The Global endometriosis market is forecast to reach USD 3.9 Billion by 2026. The global market for preterm birth was valued at $1.3 billion in 2022. The market is expected to grow to $2.6 billion by 2030. Chiima Therapeutics is looking to raise 8MM in seed funding round for commercial growth and accelerating pipeline product development. We are also looking to do a potential partnership.